Earnings call transcript: Elanco Animal Health Q4 2025 beats earnings expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy ELAN?
Source: Investing
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.680
Low
22.00
Averages
25.50
High
30.00
Current: 23.680
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Elanco Launches New Advantage™ Collar for Dogs
- Product Innovation: Elanco has launched the Advantage™ Collar for Dogs, offering up to four months of protection against fleas, ticks, and mosquitoes for dogs aged 12 weeks and older, further solidifying its leadership in the pet health market.
- Market Positioning: This collar, as an over-the-counter product, aims to provide consumers with diverse price options, adapting to various shopping channels and enhancing the brand's competitiveness in both retail and veterinary markets.
- Health Assurance: The Advantage collar effectively kills fleas and ticks while preventing ticks that may transmit diseases like Lyme disease, ensuring pets receive essential parasite control year-round.
- Sales Channels: The product will be available at pet specialty stores, grocery stores, and other retailers, reflecting Elanco's commitment to meeting consumer needs while providing pet owners with an affordable parasite control option.
See More
Elanco Launches New Advantage Collar for Dogs
- Product Innovation: Elanco's newly launched Advantage™ Collar for Dogs utilizes Pyriproxyfen as an insect growth regulator, effectively breaking the flea lifecycle and preventing reinfestation, providing up to four months of continuous protection to meet pet owners' year-round needs.
- Market Positioning: Designed for dogs aged 12 weeks and older, the collar is priced below $25 and aims to cater to consumer shopping habits through multiple retail channels, further solidifying Elanco's leadership in the retail market.
- Health Assurance: The collar not only kills fleas and ticks but also repels ticks that may transmit diseases such as Lyme disease, ensuring the health and safety of dogs during outdoor activities, especially in peak parasite seasons.
- Brand Continuity: The Advantage™ Collar is part of Elanco's 25-year brand family, enriching its over-the-counter pet product portfolio and demonstrating the company's ongoing commitment to innovation in pet health.
See More
Wall Street's Perspective on Three Stocks
- Teradata's Dim Outlook: With a consensus price target of $35.73 suggesting a 40.2% implied return, Teradata's flat billings over the past year indicate weak demand, leading to stagnant sales projections for the next 12 months, which reflects a lack of market appeal.
- Align Technology's Growth Struggles: Align Technology has a consensus price target of $201.69 with an 18.2% implied return; however, its annual revenue growth of only 2.2% over the past two years falls short of healthcare sector standards, and a 5.3 percentage point decline in adjusted operating margin signals deteriorating profitability.
- Elanco's Challenges: Elanco's consensus price target stands at $28.77, implying a 24.7% return, yet its muted 3.3% annual revenue growth over the last two years, coupled with rising costs outpacing revenue, has led to a 3.3 percentage point drop in adjusted operating margin, indicating ineffective cost management during expansion.
- Market Opportunity Analysis: While these three stocks receive positive ratings on Wall Street, their fundamentals reveal potential risks, prompting investors to seek stocks with greater growth potential to avoid losses amid market volatility.
See More
Elanco Animal Health Q4 2025 Earnings Highlights
- Significant Revenue Growth: Elanco reported $1.14 billion in revenue for Q4 2025, marking a 12% year-over-year increase, with U.S. Farm Animal and Pet Health segments growing by 17% and 10% respectively, indicating strong market performance and sustained growth potential.
- Innovation Revenue Exceeds Expectations: The company achieved $892 million in innovation revenue for 2025, the largest quarter for innovation in its history, with projections for 2026 raised to $1.15 billion, reflecting Elanco's success in new product development and confidence in future growth.
- Strategic Acquisition Plans: Elanco signed an agreement to acquire AHV International, aiming to enhance its leadership in the dairy industry in North America and Europe, which will further solidify its market share and drive future business expansion.
- Optimistic Financial Outlook: The company projects organic revenue growth of 4% to 6% for 2026, with adjusted EBITDA expected to be between $955 million and $985 million, demonstrating management's confidence in future performance and positive market demand expectations.
See More
Elanco Animal Health Surpasses Expectations with Q4 Results
- Earnings Beat: Elanco Animal Health reported an adjusted EPS of $0.13 for Q4 2025, exceeding expectations by $0.02, while revenue of $1.1B surpassed forecasts by $50M, despite a ~7% YoY decline.
- Cost-Cutting Impact: The company's bottom line was impacted by nearly $155M due to its newly launched Elanco Ascend cost-cutting initiative, alongside a $47M impairment reflecting a decline in projected sales from an acquired product group, highlighting the need for strategic adjustments.
- Full-Year Growth: For the full year 2025, Elanco achieved $4.7B in revenue, marking a ~6% YoY growth, with adjusted EPS rising ~3% YoY to $0.94, as all four business segments outperformed, benefiting from price and volume tailwinds.
- Optimistic 2026 Outlook: Elanco projected 2026 revenue between $4.95B and $5.02B, with Q1 revenue expectations of $1.280B to $1.305B, both exceeding market consensus, indicating strong confidence in future growth.
See More
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Elanco Launches New Advantage™ Collar for Dogs
- Product Innovation: Elanco has launched the Advantage™ Collar for Dogs, offering up to four months of protection against fleas, ticks, and mosquitoes for dogs aged 12 weeks and older, further solidifying its leadership in the pet health market.
- Market Positioning: This collar, as an over-the-counter product, aims to provide consumers with diverse price options, adapting to various shopping channels and enhancing the brand's competitiveness in both retail and veterinary markets.
- Health Assurance: The Advantage collar effectively kills fleas and ticks while preventing ticks that may transmit diseases like Lyme disease, ensuring pets receive essential parasite control year-round.
- Sales Channels: The product will be available at pet specialty stores, grocery stores, and other retailers, reflecting Elanco's commitment to meeting consumer needs while providing pet owners with an affordable parasite control option.
See More
Elanco Launches New Advantage Collar for Dogs
- Product Innovation: Elanco's newly launched Advantage™ Collar for Dogs utilizes Pyriproxyfen as an insect growth regulator, effectively breaking the flea lifecycle and preventing reinfestation, providing up to four months of continuous protection to meet pet owners' year-round needs.
- Market Positioning: Designed for dogs aged 12 weeks and older, the collar is priced below $25 and aims to cater to consumer shopping habits through multiple retail channels, further solidifying Elanco's leadership in the retail market.
- Health Assurance: The collar not only kills fleas and ticks but also repels ticks that may transmit diseases such as Lyme disease, ensuring the health and safety of dogs during outdoor activities, especially in peak parasite seasons.
- Brand Continuity: The Advantage™ Collar is part of Elanco's 25-year brand family, enriching its over-the-counter pet product portfolio and demonstrating the company's ongoing commitment to innovation in pet health.
See More
Wall Street's Perspective on Three Stocks
- Teradata's Dim Outlook: With a consensus price target of $35.73 suggesting a 40.2% implied return, Teradata's flat billings over the past year indicate weak demand, leading to stagnant sales projections for the next 12 months, which reflects a lack of market appeal.
- Align Technology's Growth Struggles: Align Technology has a consensus price target of $201.69 with an 18.2% implied return; however, its annual revenue growth of only 2.2% over the past two years falls short of healthcare sector standards, and a 5.3 percentage point decline in adjusted operating margin signals deteriorating profitability.
- Elanco's Challenges: Elanco's consensus price target stands at $28.77, implying a 24.7% return, yet its muted 3.3% annual revenue growth over the last two years, coupled with rising costs outpacing revenue, has led to a 3.3 percentage point drop in adjusted operating margin, indicating ineffective cost management during expansion.
- Market Opportunity Analysis: While these three stocks receive positive ratings on Wall Street, their fundamentals reveal potential risks, prompting investors to seek stocks with greater growth potential to avoid losses amid market volatility.
See More
Elanco Animal Health Q4 2025 Earnings Highlights
- Significant Revenue Growth: Elanco reported $1.14 billion in revenue for Q4 2025, marking a 12% year-over-year increase, with U.S. Farm Animal and Pet Health segments growing by 17% and 10% respectively, indicating strong market performance and sustained growth potential.
- Innovation Revenue Exceeds Expectations: The company achieved $892 million in innovation revenue for 2025, the largest quarter for innovation in its history, with projections for 2026 raised to $1.15 billion, reflecting Elanco's success in new product development and confidence in future growth.
- Strategic Acquisition Plans: Elanco signed an agreement to acquire AHV International, aiming to enhance its leadership in the dairy industry in North America and Europe, which will further solidify its market share and drive future business expansion.
- Optimistic Financial Outlook: The company projects organic revenue growth of 4% to 6% for 2026, with adjusted EBITDA expected to be between $955 million and $985 million, demonstrating management's confidence in future performance and positive market demand expectations.
See More
Elanco Animal Health Surpasses Expectations with Q4 Results
- Earnings Beat: Elanco Animal Health reported an adjusted EPS of $0.13 for Q4 2025, exceeding expectations by $0.02, while revenue of $1.1B surpassed forecasts by $50M, despite a ~7% YoY decline.
- Cost-Cutting Impact: The company's bottom line was impacted by nearly $155M due to its newly launched Elanco Ascend cost-cutting initiative, alongside a $47M impairment reflecting a decline in projected sales from an acquired product group, highlighting the need for strategic adjustments.
- Full-Year Growth: For the full year 2025, Elanco achieved $4.7B in revenue, marking a ~6% YoY growth, with adjusted EPS rising ~3% YoY to $0.94, as all four business segments outperformed, benefiting from price and volume tailwinds.
- Optimistic 2026 Outlook: Elanco projected 2026 revenue between $4.95B and $5.02B, with Q1 revenue expectations of $1.280B to $1.305B, both exceeding market consensus, indicating strong confidence in future growth.
See More
